1. Home
  2. APLS

as 05-23-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Founded: 2009 Country:
United States
United States
Employees: N/A City: WALTHAM
Market Cap: 5.2B IPO Year: 2017
Target Price: $74.38 AVG Volume (30 days): 1.5M
Analyst Decision: Strong Buy Number of Analysts: 16
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.45 EPS Growth: N/A
52 Week Low/High: $19.83 - $94.75 Next Earning Date: 05-07-2024
Revenue: $524,070,000 Revenue Growth: 394.93%
Revenue Growth (this year): 104.94% Revenue Growth (next year): 48.38%

Share on Social Networks:

Stock Insider Trading Activity of Apellis Pharmaceuticals Inc. (APLS)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Deschatelets Pascal APLS Chief Scientific Officer May 8 '24 Sell $42.15 56,335 $2,374,542.78 1,138,555 SEC Form 4
Deschatelets Pascal APLS Chief Scientific Officer May 8 '24 Sell $42.85 22,472 $962,902.73 1,116,083 SEC Form 4
Deschatelets Pascal APLS Chief Scientific Officer May 8 '24 Sell $44.03 100 $4,402.50 1,115,983 SEC Form 4
Deschatelets Pascal APLS Chief Scientific Officer Apr 8 '24 Sell $54.12 64,379 $3,483,966.15 1,120,711 SEC Form 4
Deschatelets Pascal APLS Chief Scientific Officer Apr 8 '24 Sell $54.92 4,728 $259,639.07 1,115,983 SEC Form 4
Sullivan Timothy Eugene APLS Chief Financial Officer Apr 1 '24 Sell $58.66 4,000 $234,640.00 93,338 SEC Form 4
DeLong Mark Jeffrey APLS Chief Business & Strat Officer Mar 18 '24 Sell $56.90 9,913 $564,049.70 54,693 SEC Form 4
Chopas James George APLS VP/Chief Accounting Officer Mar 15 '24 Sell $56.46 184 $10,388.82 38,883 SEC Form 4
Nicholson Nur APLS Chief Technical Officer Mar 13 '24 Sell $57.31 7,768 $445,160.78 59,739 SEC Form 4
Nicholson Nur APLS Chief Technical Officer Mar 13 '24 Sell $58.13 3,452 $200,676.84 56,287 SEC Form 4
Deschatelets Pascal APLS Chief Scientific Officer Mar 8 '24 Sell $61.88 42,750 $2,645,173.35 1,142,340 SEC Form 4
Deschatelets Pascal APLS Chief Scientific Officer Mar 8 '24 Sell $62.69 26,257 $1,646,040.83 1,116,083 SEC Form 4
Deschatelets Pascal APLS Chief Scientific Officer Mar 8 '24 Sell $63.35 100 $6,335.00 1,115,983 SEC Form 4
Sullivan Timothy Eugene APLS Chief Financial Officer Mar 1 '24 Sell $62.86 4,000 $251,440.00 95,338 SEC Form 4
Sullivan Timothy Eugene APLS Chief Financial Officer Mar 1 '24 Sell $63.95 2,000 $127,900.00 93,338 SEC Form 4
Watson David O. APLS General Counsel Feb 12 '24 Sell $67.77 781 $52,925.95 103,390 SEC Form 4
Townsend Adam J. APLS Chief Commercial Officer Feb 12 '24 Sell $67.77 1,148 $77,796.40 92,453 SEC Form 4
Deschatelets Pascal APLS Chief Scientific Officer Feb 12 '24 Sell $67.77 1,148 $77,796.40 1,115,983 SEC Form 4
Sullivan Timothy Eugene APLS Chief Financial Officer Feb 12 '24 Sell $67.77 1,431 $96,974.43 93,338 SEC Form 4
Francois Cedric APLS Chief Executive Officer Feb 12 '24 Sell $67.77 3,962 $268,492.46 313,662 SEC Form 4
DeLong Mark Jeffrey APLS Chief Business & Strat Officer Feb 12 '24 Sell $67.77 597 $40,456.84 64,606 SEC Form 4
Lewis Karen APLS Chief People Officer Jan 29 '24 Sell $64.14 367 $23,538.72 47,270 SEC Form 4
Lewis Karen APLS Chief People Officer Jan 29 '24 Sell $65.53 883 $57,862.99 46,387 SEC Form 4
Francois Cedric APLS Chief Executive Officer Jan 29 '24 Sell $64.14 2,843 $182,344.90 317,624 SEC Form 4
Nicholson Nur APLS Chief Technical Officer Jan 29 '24 Sell $64.14 835 $53,555.40 67,507 SEC Form 4